Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving First Citizens BancShares and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On January 23, 2026, First Citizens reported its fourth-quarter financial results for 2025, revealing an efficiency ratio of 64.5%, which missed analyst expectations and worsened compared to the previous year [3]. - The company provided a weaker outlook, indicating expected deterioration in revenue and weak projections for net interest income in the upcoming year [3]. Stock Market Reaction - Following the announcement of the financial results, First Citizens' stock price fell by $186.97 per share, or 8.49%, closing at $2,016.56 per share on January 23, 2026 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Capital One Financial Corporation and its officers or directors [1]. Financial Performance - On January 22, 2026, Capital One reported Q4 2025 earnings per share of $3.86, which fell short of analyst expectations of $4.14 [3]. - The company's efficiency ratio was reported at 60%, also missing analyst expectations [3]. - Following the earnings report, Capital One's stock price dropped by $17.77, or 7.56%, closing at $217.30 per share on January 23, 2026 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving BlackRock TCP Capital Corp and its officers or directors [1] Group 1: Company Performance - On January 23, 2026, BlackRock TCP reported a 19% decline in the net asset value of its private corporate loans, attributed to a significant increase in nonperforming loans [3] - Following this announcement, BlackRock TCP's stock price decreased by $0.76 per share, representing a 12.97% drop, closing at $5.10 per share on January 26, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of BlackRock TCP to discuss claims related to the company's potential involvement in securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors, following a significant stock price drop after the FDA's Complete Response Letter regarding a new drug application [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol excess [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter regarding its drug relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter concerning Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is currently investigating claims on behalf of investors of Corcept, suggesting potential legal ramifications for the company and its leadership [1][4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving REGENXBIO Inc. and its officers or directors [1] Group 1: Company Developments - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111 for treating MPS I due to a case of neoplasm in a participant [3] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [3] - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share on the same day [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is actively seeking investors of REGENXBIO to contact them regarding the investigation into potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zenas BioPharma, Inc. and its officers or directors, following disappointing results from a clinical trial that negatively impacted the company's stock price [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. is a publicly traded company on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of its drug obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas; however, analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [3]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [3]. - On a subsequent conference call, the CEO expressed disappointment regarding the drug's hazard ratio, which did not meet expectations, leading to an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Aquestive Therapeutics, Inc. and its officers and directors [1]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is currently facing scrutiny regarding its New Drug Application (NDA) for Anaphylm, as the FDA has identified deficiencies that prevent further discussions on labeling and post-marketing commitments [3]. - Following the announcement of the FDA's findings, Aquestive's stock price experienced a significant decline, falling by $2.30 per share, or 37.04%, closing at $3.91 per share on January 9, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is leading the investigation into the claims against Aquestive [1][4]. - The firm has a long history of advocating for victims of securities fraud and has successfully recovered multimillion-dollar damages for class members [4].

Core Viewpoint - PDD Holdings Inc. is under investigation for potential securities fraud and unlawful business practices, following a broader probe initiated by the Chinese government involving over 100 regulators [3]. Group 1: Investigation Details - The investigation by the Chinese government includes allegations of misconduct such as fraudulent deliveries and taxation issues [3]. - The probe was partially triggered by an incident of physical violence between PDD employees and inspectors from the State Administration for Market Regulation (SAMR) [3]. Group 2: Market Reaction - Following the news of the investigation, PDD's American Depositary Receipt (ADR) price decreased by $2.30, or 2.15%, closing at $104.46 on January 20, 2026 [4]. Group 3: Legal Representation - Pomerantz LLP is investigating claims on behalf of PDD investors and is recognized for its expertise in corporate, securities, and antitrust class litigation [1][5].

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Klarna Group PLC (“Klarna” or the “Company”) (NYSE: KLAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Klarna and certain of its officer ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Disc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 15, 202 ...